Tenofovir Disoproxil Fumarate Use during Pregnancy and Infant Bone Health: the Tenofovir in Pregnancy Pilot Study

Pediatr Infect Dis J. 2018 Nov;37(11):e264-e268. doi: 10.1097/INF.0000000000002152.


The effects of maternal tenofovir use on infant bone mineral content (BMC) and bone mineral density (BMD) were evaluated in a pilot study of HIV/Hepatitis B-coinfected pregnant women in China. BMD and BMC were assessed at age 6 months of life in 14 tenofovir-exposed and 13 unexposed infants. Trends toward lower BMC and BMD were observed in infants exposed to maternal tenofovir but were not statistically significant.

Publication types

  • Clinical Trial, Phase II
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Anti-HIV Agents / adverse effects*
  • Anti-HIV Agents / therapeutic use
  • Bone Density / drug effects*
  • Bone and Bones / drug effects*
  • China
  • Coinfection / drug therapy
  • Coinfection / virology
  • Female
  • HIV Infections / drug therapy
  • Hepatitis B / drug therapy
  • Humans
  • Infant
  • Infant Health*
  • Pilot Projects
  • Pregnancy
  • Pregnancy Complications, Infectious / drug therapy
  • Tenofovir / adverse effects*
  • Tenofovir / therapeutic use
  • Young Adult


  • Anti-HIV Agents
  • Tenofovir